Purpose: We evaluated the pharmacokinetics of intravitreally injected ranibizumab and aflibercept, and their effects on @entity7 in the @entity7462 of vitrectomized and nonvitrectomized macaque eyes. Methods: Intravitreal ranibizumab (IVR; 0.5 mg/50  L) or @entity3853 ( @entity3853 ; 2 mg/50  L) was injected into the previously vitrectomized right eyes of three macaques and nonvitrectomized right eyes of three macaques. The left eyes served as controls (nonvitrectomized, noninjected). @entity7462 was obtained from both eyes just before injection and on days 1 and 3, and weeks 1 to 8 after IVR and @entity3853 . The ranibizumab, aflibercept, and @entity7 concentrations were measured using enzyme-linked immunosorbent assays. Results: The half-lives in @entity7462 of nonvitrectomized and vitrectomized eyes were, respectively, 2.3 and 1.4 days for ranibizumab, and 2.2 and 1.5 days for aflibercept. Concentration of @entity7 was decreased below the limit of detection (LOD) by IVR for 3 weeks in nonvitrectomized eyes and 1 week in vitrectomized eyes, respectively, and by @entity3853 for 6 weeks in nonvitrectomized eyes and 4 weeks in vitrectomized eyes, respectively. In the untreated control eyes, the ranibizumab and aflibercept concentrations were below the LOD, and the @entity7 aqueous concentrations remained unchanged after IVR and decreased for 3 days after @entity3853 . Conclusions: Intravitreally injected ranibizumab and aflibercept have similar half-lives in @entity7462 and shorter half-lives in vitrectomized eyes. Compared to IVR, @entity3853 suppresses @entity7 level for a longer time period.

Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous XXXX Level in Vitrectomized and Nonvitrectomized Macaque Eyes.

@entity7462 :: ('MESH:C562390', 'Disease') :: ['aqueous humor', 'Aqueous humor'] @entity3853 :: ('MESH:C536369', 'Disease') :: ['intravitreal aflibercept', 'IVA'] @entity7 :: ('7422', 'Gene') :: ['VEGF']
@entity7 :: (7422,Gene) :: ['VEGF']
